China to audit 77 drugmakers, including Lilly, after $4.3B scandal
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Indianapolis-based Lilly reported first quarter revenue of $5.09 billion, up 3% from a year ago but below analyst expectations of $5.2 billion. Sales of several of Lilly’s top drugs missed expectations.
Local tech firm, Springbuk, has grown from 16 to 102 employees in a little more than two years. A recently released product upgrade the company is calling “a game changer” is spurring another round of serious growth.
Paul Elmer, former owner and CEO of Pharmakon Pharmaceuticals in Noblesville, was convicted in federal court of nine counts of adulterating drugs and one count of conspiracy. He was acquitted of an additional count of obstruction of justice.
As Congress and President Donald Trump's administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome.
The proposed tax abatement is related to a $91 million investment the company is making in a building at the Lilly Technology Center on Kentucky Avenue.
The state’s largest health system said earnings from operations climbed 4 percent, but investment losses pulled down total earnings by 70 percent.
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
For hospitals, maternity care builds relationships with young families that often last for decades. About 40 percent of women experience their first encounter with hospitals for reproductive services.
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Lartruvo shouldn’t be started in new patients, and those patients already taking it should ask their doctors if they should continue, U.S. regulators said, following a key study that failed to show the medicine prolonged lives.
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.
The dispute between the world’s largest retail chain and the prominent pharmacy-benefits manager could roil the business of filling prescriptions.
Eli Lilly and Co. won’t put the price of its prescription drugs in television ads, as the Trump administration has called for pharmaceutical companies to do, but will begin promoting a website where prices are available.
Drug industry analysts on Monday applauded Eli Lilly and Co.’s pending $8 billion cash deal to buy a startup that focuses on oncology, which has become a prime focus for the pharma giant in the last year.
Pharmaceutical giants Merck & Co. and Pfizer Inc. were kings of the Dow Jones industrial index during the year, while Eli Lilly and Co. was among the 20 largest gainers on the S&P 500.
Makers of antidepressants and antipsychotics like Indianapolis-based Eli Lilly and Co., AstraZeneca, Pfizer, Allergan, Bausch Health and Otsuka Holdings might face new challenges and may be deterred from price hikes.